190 related articles for article (PubMed ID: 30148988)
1. Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma.
Giles KM; Rosenbaum BE; Berger M; Izsak A; Li Y; Illa Bochaca I; Vega-Saenz de Miera E; Wang J; Darvishian F; Zhong H; Osman I
J Invest Dermatol; 2019 Feb; 139(2):430-438. PubMed ID: 30148988
[TBL] [Abstract][Full Text] [Related]
2. Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival.
Roh MR; Gupta S; Park KH; Chung KY; Lauss M; Flaherty KT; Jönsson G; Rha SY; Tsao H
J Invest Dermatol; 2016 May; 136(5):1002-1011. PubMed ID: 26854490
[TBL] [Abstract][Full Text] [Related]
3. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.
Bucheit AD; Chen G; Siroy A; Tetzlaff M; Broaddus R; Milton D; Fox P; Bassett R; Hwu P; Gershenwald JE; Lazar AJ; Davies MA
Clin Cancer Res; 2014 Nov; 20(21):5527-36. PubMed ID: 25165098
[TBL] [Abstract][Full Text] [Related]
4. Methylation and mutation of the inhibin‑α gene in human melanoma cells and regulation of PTEN expression and AKT/PI3K signaling by a demethylating agent.
Ko H; Ahn HJ; Kim YI
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34958114
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of DJ-1 expression in melanoma regulates PTEN/AKT pathway for cell survival and migration.
Lee YJ; Kim WI; Park TH; Bae JH; Nam HS; Cho SW; Choi YJ; Lee SH; Cho MK
Arch Dermatol Res; 2021 Sep; 313(7):583-591. PubMed ID: 32959108
[TBL] [Abstract][Full Text] [Related]
6. Methylation of PTEN as a prognostic factor in malignant melanoma of the skin.
Lahtz C; Stranzenbach R; Fiedler E; Helmbold P; Dammann RH
J Invest Dermatol; 2010 Feb; 130(2):620-2. PubMed ID: 19798057
[No Abstract] [Full Text] [Related]
7. Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma.
Mitra S; Lauss M; Cabrita R; Choi J; Zhang T; Isaksson K; Olsson H; Ingvar C; Carneiro A; Staaf J; Ringnér M; Nielsen K; Brown KM; Jönsson G
Mol Oncol; 2020 May; 14(5):933-950. PubMed ID: 32147909
[TBL] [Abstract][Full Text] [Related]
8. Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma.
de Unamuno Bustos B; Murria Estal R; Pérez Simó G; Simarro Farinos J; Pujol Marco C; Navarro Mira M; Alegre de Miquel V; Ballester Sánchez R; Sabater Marco V; Llavador Ros M; Palanca Suela S; Botella Estrada R
Br J Dermatol; 2018 Aug; 179(2):394-404. PubMed ID: 29278418
[TBL] [Abstract][Full Text] [Related]
9. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
[TBL] [Abstract][Full Text] [Related]
10. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer.
Song M; Chen D; Lu B; Wang C; Zhang J; Huang L; Wang X; Timmons CL; Hu J; Liu B; Wu X; Wang L; Wang J; Liu H
PLoS One; 2013; 8(6):e65821. PubMed ID: 23785454
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of the PTEN gene in melanoma.
Mirmohammadsadegh A; Marini A; Nambiar S; Hassan M; Tannapfel A; Ruzicka T; Hengge UR
Cancer Res; 2006 Jul; 66(13):6546-52. PubMed ID: 16818626
[TBL] [Abstract][Full Text] [Related]
12. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
[TBL] [Abstract][Full Text] [Related]
13. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation.
Mikhail M; Velazquez E; Shapiro R; Berman R; Pavlick A; Sorhaindo L; Spira J; Mir C; Panageas KS; Polsky D; Osman I
Clin Cancer Res; 2005 Jul; 11(14):5153-7. PubMed ID: 16033830
[TBL] [Abstract][Full Text] [Related]
14. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
[TBL] [Abstract][Full Text] [Related]
15. PTEN Methylation Dependent Sinonasal Mucosal Melanoma.
Lee SH; Roh MR; Kang B; Park KH; Kim SH; Lee SE; Rha SY
Cancer Res Treat; 2016 Apr; 48(2):853-8. PubMed ID: 25797573
[TBL] [Abstract][Full Text] [Related]
16. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
17. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma.
Abdel-Rahman MH; Yang Y; Zhou XP; Craig EL; Davidorf FH; Eng C
J Clin Oncol; 2006 Jan; 24(2):288-95. PubMed ID: 16344319
[TBL] [Abstract][Full Text] [Related]
18. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
Jain A; Tripathi R; Turpin CP; Wang C; Plattner R
Oncogene; 2017 Aug; 36(32):4585-4596. PubMed ID: 28368422
[TBL] [Abstract][Full Text] [Related]
19. Interplay between PREX2 mutations and the PI3K pathway and its effect on epigenetic regulation of gene expression in NRAS-mutant melanoma.
Lissanu Deribe Y
Small GTPases; 2016 Jul; 7(3):178-85. PubMed ID: 27111337
[TBL] [Abstract][Full Text] [Related]
20. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.
Wang X; Cao X; Sun R; Tang C; Tzankov A; Zhang J; Manyam GC; Xiao M; Miao Y; Jabbar K; Tan X; Pang Y; Visco C; Xie Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WWL; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Winter JN; Piris MA; Li S; Miranda RN; Medeiros LJ; Li Y; Xu-Monette ZY; Young KH
Neoplasia; 2018 Jun; 20(6):574-593. PubMed ID: 29734016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
